Meta-analysis indicates dose-dependent effects of SGLT2 inhibitors on kidney outcomes in diabetic patients, suggesting careful drug selection is essential.
SGLT2 inhibitors confer renal protection in both diabetic and non-diabetic populations, supporting their use in CKD management across a broad spectrum of patients. However, careful drug selection is warranted in diabetic patients at risk for DKA.
No takes yet. Share an insight, caveat, or question.
Qian et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: